Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Brief Summary: Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.


Options:
A: Arm Label: Wellness Education Control Condition; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wellness Education Control Condition | Arm Label: Mindfulness Training (MT); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Training | Arm Label: Mindfulness Training Plus IE (MT+IE); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Training Plus IE | Intervention Type: BEHAVIORAL; Name: Wellness Education Control Condition; Assigned to Arm(s): Wellness Education Control Condition | Intervention Type: BEHAVIORAL; Name: Mindfulness Training; Assigned to Arm(s): Mindfulness Training (MT) | Intervention Type: BEHAVIORAL; Name: Mindfulness Training Plus IE; Assigned to Arm(s): Mindfulness Training Plus IE (MT+IE)
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: Mindfulness-Based Treatment Group (MBAT); Type: EXPERIMENTAL; Interventions: Behavioral: MBAT Group Therapy, Drug: Nicotine | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Group Therapy | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Individual Therapy | Intervention Type: BEHAVIORAL; Name: MBAT Group Therapy; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT) | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT), Standard Care Group, Usual Care Group | Intervention Type: BEHAVIORAL; Name: Group Therapy; Assigned to Arm(s): Standard Care Group | Intervention Type: BEHAVIORAL; Name: Individual Therapy; Assigned to Arm(s): Usual Care Group

Answer: C